Skip to main content

Table 1 Characteristics of Breast Cancer Cases and Population Controls in the OFBCR

From: Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis

Characteristic

All Cases (N = 1,115)

Cases with Clinical Data (N = 967)

All Controls (N = 710)

Age1

   

Mean ± SD

48.6 ± 9.0

48.9 ± 9.2

48.5 ± 9.1

Menopausal Status2

   

Pre-

828 (75.0%)

710 (73.7%)

497 (70.2%)

Post-

276 (25.0%)

253 (26.3%)

211 (29.8%)

Ethnicity

   

White

1062 (95.3%)

899 (93.0%)

653 (95.2%)

Non-White

53 (4.7%)

68 (7.0%)

33 (4.8%)

Parity

   

Nulliparous

201 (19.5%)

204 (21.5%)

106 (15.0%)

1–2 child

620 (60.2%)

562 (59.2%)

434 (61.2%)

> 3 children

209 (20.3%)

183 (19.3%)

168 (23.8%)

First-degree Family History3

   

No

731 (65.6%)

618 (63.9%)

641 (90.3%)

Yes

384 (34.4%)

349 (36.1%)

69 (9.7%)

OFBCR Defined Genetic Risk Case4

   

No

311 (27.9%)

281 (29.1%)

NA

Yes

804 (72.1%)

686 (70.9%)

 

Histology

   

Infiltrating Ductal No Special Type

--

824 (90.2%)

NA

Lobular

 

65 (7.1%)

 

Other Special Type5

 

25 (2.7%)

 

T Stage

   

pT1 (<2 cm)

--

607 (64.0%)

NA

pT2 (2–5 cm)

 

281 (29.6%)

 

pT3/pT4 (>5 cm)

 

34 (3.6%)

 

pTx (not accessible)

 

26 (2.7%)

 

# Positive Lymph Nodes

   

None

--

538 (56.6%)

NA

1–3

 

243 (25.6%)

 

≥4

 

113 (11.9%)

 

Nx (not accessible)

 

56 (5.9%)

 

Grade

   

I (well differentiated)

--

194 (21.5%)

NA

II (moderately differentiated)

 

351 (38.8%)

 

III (poorly differentiated)

 

359 (39.7%)

 

Lymphatic Vessel Invasion

   

Negative

--

582 (66.1%)

NA

Positive

 

299 (33.9%)

 

Estrogen Receptor Status

   

Negative

--

230 (24.5%)

NA

Equivocal

 

49 (5.2%)

 

Positive

 

659 (70.3%)

 

Progesterone Receptor Status

   

Negative

--

259 (27.8%)

NA

Equivocal

 

55 (5.9%)

 

Positive

 

618 (66.3%)

 
  1. 1 age at diagnosis for cases and age at interview for controls; 2 peri-menopausal women are grouped with pre-menopausal women; 3 self-reported cancer histories of breast or ovarian cancer; 4 criteria used by the OFBCR to oversample more informative cases in order to enrich registry for genetically predisposed individuals (see methods); 5 includes medullary, tubular, cribriform, micropapillary, mucinous, metaplastic; NA, not applicable